These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

767 related items for PubMed ID: 26923521

  • 1. Olfactory impairment predicts cognitive decline in early Parkinson's disease.
    Fullard ME, Tran B, Xie SX, Toledo JB, Scordia C, Linder C, Purri R, Weintraub D, Duda JE, Chahine LM, Morley JF.
    Parkinsonism Relat Disord; 2016 Apr; 25():45-51. PubMed ID: 26923521
    [Abstract] [Full Text] [Related]

  • 2. Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease.
    Skogseth RE, Bronnick K, Pereira JB, Mollenhauer B, Weintraub D, Fladby T, Aarsland D.
    J Parkinsons Dis; 2015 Apr; 5(4):783-92. PubMed ID: 26599300
    [Abstract] [Full Text] [Related]

  • 3. Clinical variables and biomarkers in prediction of cognitive impairment in patients with newly diagnosed Parkinson's disease: a cohort study.
    Schrag A, Siddiqui UF, Anastasiou Z, Weintraub D, Schott JM.
    Lancet Neurol; 2017 Jan; 16(1):66-75. PubMed ID: 27866858
    [Abstract] [Full Text] [Related]

  • 4. Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer's disease-associated biomarkers alterations among de novo Parkinson's disease patients: a prospective cohort study.
    Liu T, Zuo H, Ma D, Song D, Zhao Y, Cheng O.
    J Neuroinflammation; 2023 Jul 20; 20(1):167. PubMed ID: 37475029
    [Abstract] [Full Text] [Related]

  • 5. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression.
    Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB.
    Brain; 2017 Jul 01; 140(7):1959-1976. PubMed ID: 28549077
    [Abstract] [Full Text] [Related]

  • 6. Amyloid-β and α-synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease.
    Stav AL, Aarsland D, Johansen KK, Hessen E, Auning E, Fladby T.
    Parkinsonism Relat Disord; 2015 Jul 01; 21(7):758-64. PubMed ID: 25971633
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Olfactory function and neuropsychological profile to differentiate dementia with Lewy bodies from Alzheimer's disease in patients with mild cognitive impairment: A 5-year follow-up study.
    Yoon JH, Kim M, Moon SY, Yong SW, Hong JM.
    J Neurol Sci; 2015 Aug 15; 355(1-2):174-9. PubMed ID: 26076880
    [Abstract] [Full Text] [Related]

  • 10. Olfaction and taste in Parkinson's disease: the association with mild cognitive impairment and the single cognitive domain dysfunction.
    Cecchini MP, Federico A, Zanini A, Mantovani E, Masala C, Tinazzi M, Tamburin S.
    J Neural Transm (Vienna); 2019 May 15; 126(5):585-595. PubMed ID: 30911822
    [Abstract] [Full Text] [Related]

  • 11. Parkinson's disease: evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study.
    Lerche S, Wurster I, Röben B, Machetanz G, Zimmermann M, Bernhard F, Stransky E, Deuschle C, Schulte C, Hansson O, Zetterberg H, Gasser T, Berg D, Maetzler W, Brockmann K.
    J Neurol Neurosurg Psychiatry; 2019 Feb 15; 90(2):165-170. PubMed ID: 30254084
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. CSF β-Amyloid 1-42 Predicts Progression to Cognitive Impairment in Newly Diagnosed Parkinson Disease.
    Terrelonge M, Marder KS, Weintraub D, Alcalay RN.
    J Mol Neurosci; 2016 Jan 15; 58(1):88-92. PubMed ID: 26330275
    [Abstract] [Full Text] [Related]

  • 14. Varying strength of cognitive markers and biomarkers to predict conversion and cognitive decline in an early-stage-enriched mild cognitive impairment sample.
    Egli SC, Hirni DI, Taylor KI, Berres M, Regeniter A, Gass A, Monsch AU, Sollberger M.
    J Alzheimers Dis; 2015 Jan 15; 44(2):625-33. PubMed ID: 25322924
    [Abstract] [Full Text] [Related]

  • 15. CSF biomarker changes precede symptom onset of mild cognitive impairment.
    Moghekar A, Li S, Lu Y, Li M, Wang MC, Albert M, O'Brien R, BIOCARD Research Team.
    Neurology; 2013 Nov 12; 81(20):1753-8. PubMed ID: 24132375
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Performance of aβ1-40, aβ1-42, total tau, and phosphorylated tau as predictors of dementia in a cohort of patients with mild cognitive impairment.
    Parnetti L, Chiasserini D, Eusebi P, Giannandrea D, Bellomo G, De Carlo C, Padiglioni C, Mastrocola S, Lisetti V, Calabresi P.
    J Alzheimers Dis; 2012 Nov 12; 29(1):229-38. PubMed ID: 22232006
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.